We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arthro Kinetics | LSE:AKI | London | Ordinary Share | GB00B0XQ4466 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 0.10 | GBX |
Arthro Kinetics (AKI) Share Charts1 Year Arthro Kinetics Chart |
|
1 Month Arthro Kinetics Chart |
Intraday Arthro Kinetics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/9/2008 | 22:54 | Active | 1 |
| 01/5/2008 | 23:00 | Rangers FC | 3 |
| 07/11/2007 | 09:03 | Arthro Kinetics - New Issue - Pro Frankensteins | 154 |
| 03/3/2006 | 16:21 | Athro Kinetics - New Issue - Pro Frankensteins | 2 |
| 03/3/2006 | 16:02 | Arhtro Kinetics - New Issue - Pro Frankensteins | 5 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 21/6/2007 11:06 by oracle5 A few more buys and we will be back to last weeks level.Anyone thinking of selling hold on as long as you can to get the best price. |
Posted at 21/6/2007 09:46 by oracle5 The run up to results and the results will push the price back up to and above the 20 pence level.The pull back in price last week was on very low volume and the price was rising on very small buys. |
Posted at 13/6/2007 13:51 by hopestaruk Arthro Kinetics European PatentRNS Number:2927Y Arthro Kinetics plc 13 June 2007 Press Release Arthro Kinetics plc - granted European patent WEDNESDAY, 13th June 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro Kinetics"), the orthopedics company dedicated to regenerating joint mobility and spinal disc function, announces that its wholly owned subsidiary Arthro Kinetics AG has been granted a European patent (EP 1 289 574) for "Cartilage Replacement and Methods for the Production Thereof". Jason Loveridge, CEO of Arthro Kinetics commented: "This is excellent news for Arthro Kinetics and validation of the novelty of our R&D and product portfolio for cartilage regeneration. This patent extends coverage for our core proprietary technology - from which our first product CaReS(R) emerged onto the market in 2003 - to an additional 19 European countries beyond Germany, where the original application was filed in May 2001. We are continuing to pursue protection across all key commercial markets and, in this respect, the European patent represents an important piece of intellectual property protecting our core technology and portfolio of products for cartilage regeneration". END Contact Jason Loveridge Tel: +49 (0)711 305 110 70 Chief Executive, Arthro Kinetics plc |
Posted at 08/6/2007 09:46 by oracle5 This looks like a rise up to possible resistance at 22 pence is now on the cards as it does not take much buying to move the price. |
Posted at 04/6/2007 11:27 by katylied Always a good sign when Huge arrives looking for value.But caution Huge. AKI spend alot on trying to shift their product. I doubt £6m is still left... |
Posted at 27/3/2007 16:22 by katylied Basically, the share is now down to cash-value. Historic cash-burn has however been high, so could yet see a discount to cash, if good news proves elusive. At this point some very carefull analysis of 2007 trading prospects is required. How much cash out, and how much in... Any volunteers?... |
Posted at 27/2/2007 19:00 by katylied So... What is it all about?... My take on the state of play...At present AKI has 50m authorised shares of 20p nominal value. There are ~28m shares (fully paid) in issue. The current MktCap at today's mid of 14p, is therefore ~£4m. The company is still loss-making. There is ~£1.9m cash on the balance-sheet, but also a similar amount of debt. The EGM called for 22/03/2007 is to authorise a capital-reorganisati So... subject to that EGM, AKI will be reorganised to have 200m (4:1) authorised new shares of 5p nomial value. The 27,600,481 old (20p) shares already in issue will be re-nominalised (1:1) at 5p (the additional new 15p shares are simply a device to achieve that end. They will always be worthless and can be ignored). There will be a subscription of ~44m new (5p) shares at 10p/share and a placing of 16m new (5p) shares at 10p/share. This will raise ~£6m gross and increase the total shares in issue to ~88m. There will also be warrants for future issue of an additional ~30m shares at 20p/share and options for a further ~10% of the enlarged share issue, at prices from 15p to 50p. At today's 14p mid-price, the post EGM MktCap would be ~£12m with net balance-sheet cash of ~£6m... The new funds will cover a further 12 months, but beyond that company trading will have to improve substantially. The size of future losses will be key. If the cash just burns away, then a ~£12m MktCap looks much too high. In that event, the share-price could halve, rather sooner than it might double... |
Posted at 27/2/2007 10:50 by learntlesson Hey Katy, _ haven't looked at AKI for a while - but from my understanding they took a hit in November when the Germans told them they needed an authorisation to by the tissue cultures, and then on 30th of Jan this year they got that authorisation. I think in light of the possible value, some of that dilution may already have been accounted for. This could see a nice reversal? |
Posted at 25/9/2006 10:03 by jonwig Yes, adgd2 - cost of sales shouldn't look like that!Not remarked on was this (underlined bits) from the AFX report on the 22 August RNS: LONDON (AFX) - Orthopaedics group Arthro Kinetics PLC moved to reassure the market and said it is unaware of any fundamental reason for the plunge in its share price, which more than halved yesterday after a shareholder sold 150,000 shares at a significant discount to the market price. A seller sold the shares at 30 pence each, 75 pct below the stock's opening price. The move caused the share price to drop from 111.5 to 55 pence Monday. The German-based company, which makes a range of biologic implants for joints and the spine, floated on AIM at the beginning of March, selling shares at 120 pence each. The group's house broker Nomura Code Securities said this morning that in its view nothing has changed the fundamental prospects of the company since the IPO, and that the scale of yesterday's move was more reflective of the illiquidity of the stock. The shares sold represented a 0.5 pct stake. Nomura Code expects Arthro to break even next year. "Operationally the company seems to be progressing to plan," it wrote. At 12.40 pm shares in the company were trading 1.5 pence lower at 53.5, giving a market value of 15 mln stg. I'd expect a broker note with some projections after these numbers, and would hope that this rather high cashburn is start-up and training costs rather than what to expect as an ongoing feature. Break even next year?? |
Posted at 23/8/2006 11:27 by jonwig Edited transcript of the interview on WallStreetReporter:WSR: Give us a brief overview of the company. AKI: We started as Ars Arthro in 1999, focusing on biological, cellular, and acellular regeneration. We grew quickly, bringing the first products into human clinical trial use in October of 2002. In the beginning of 2004, we started marketing a product called CaReS, an autologous cellular matrix product for focal cartilage defects of the knee. Following that, we joined forces with Endospine Kinetics, an innovative start-up company in the U.K., which focused on minimally-invasive access systems and new techniques for spinal surgery. The vision behind that was to combine innovative, regenerative technologies with minimally-invasive access systems. With that background, we took the first step with the public listing and then positioned ourselves to bring these technologies not only together but also to internationalize the operations, which have been focused in the German-speaking market. WSR: Give us some insight into the overall size of the market and some of the drivers behind this space. AKI: These were previously traditional markets in other words, where symptoms were addressed by either symptomatic pain management therapy or joint replacement products. It's been only ten years since the first biological product has been used in the knee joint it's a new and developing market. With the technology we have, we are confident we can make joint resurfacing a realistic option and an additional treatment alternative for the orthopedic surgeon, which will open up at least 50% of the existing knee replacement market, or U.S.$3 billion to U.S.$4 billion worldwide. WSR: Talk about the company's products, services, and technologies, as well as available market applications. AKI: On the knee side, we would be talking about a real total option -- various cartilage replacement products besides the first product we have on the market. There will be acellular products coming out in the European market by the end of this year and a further complete resurfacing product is planned here in Europe for the beginning of 2007. On top of that, there is a meniscus project in development, which should go into human trials by the end of next year, as well as a ligament project. We believe these are required to meet the vision we have; when we go to the spinal side, we can now use that access system to put in biological nucleus regeneration, which will be a cascade of four to five different products, depending on the degree of disc degeneration -- human trials are only two years away. WSR: What is unique about Arthro Kinetics that sets it apart from its competitors? AKI: There has often been a misconception of regenerative technologies, particularly as they have existed up until now, not being economically viable. We believe we have addressed that issue with this matrix technology. This matrix is the core technology -- we can use that to embed cells or modify the matrix itself for the various indications and usages we are addressing. With that same advantage on the cellular side, it makes the process only ten days at the present time -- we can cut it down to a week. In addition, having the matrix as a core technology allows us internationally to decentralize the seeding part of the process, to use supply and license agreements and joint venture partners to go after the large emerging markets. WSR: Tell us how the company is competing at present in terms of present technologies and products. AKI: The most important trend is always commercial trend; the fact that there have always been significant biological products, which have now become really blockbuster products, especially on the BMP side, that has been a successful product, despite the long years and significant investments involved in those kinds of projects. That will pave the way for other biological and cellular products and other regenerative medicine products to be as successful as their predecessors. The second major trend is also a change in the mindset of the surgeons, because we are developing technologies that make the application of these products, especially in the cellular area, easier for the surgeon to apply, with very short operative times, often on an outpatient basis. WSR: How is the company positioned to capitalize on those trends? AKI: Having this matrix technology which makes specialty cellular therapy an implant that can be shaped and sized easily intraoperatively; it can be adapted to meet the different indications and applications required such as cartilage, meniscus, and ligaments, as well as disc degeneration. It's the first time that broad an application has been available in this form. WSR: What are some of the recent highlights and milestones the company has achieved? AKI: During the first quarter this year, we were very concerned about our resources being overstretched. The results were the opposite. Our company grew 100% over 2005. After that IPO, within the last two or three months, we've been able to recognize significant milestones in signing agreements to generate revenues over the next two or three years in various parts of the business, including distribution agreements in the patient markets in Europe, on top of that getting regulatory processes and the first approvals for a part of the product range in the U.S. WSR: Give us some insight into the key goals and strategies necessary for the company to ensure success. AKI: Getting experienced senior people into the various geographic locations in Asia, U.S. and Europe was very successfully started; we need to put additional resources in place in the next few months. We need to generate significant revenue growth and realize the potential we have in front of us with the technology at our disposal. WSR: When we talk about the company and its market valuation on the AIM, are there any peers we should look to in understanding and reconciling market valuation? AKI: When we look at some of the analyst reports, obviously, the peer group evaluation that they use, mainly in the orthopedic space, classical orthopedic companies, but also in the biologics and biomaterials area, those we believe would be companies that would be comparable. WSR: Give us some insight into any underlying strategies for existing partners or future alliances. AKI: On the R&D side, we look to keep good alliances, particularly on the university level, to see new development technologies coming ahead that might augment what we are doing, and have in terms of our technology portfolio and add to that wherever possible. In addition, on the distribution side, strategic alliances can be important in the major markets, to get excellent market coverage and quick growth into the market with the innovative technologies we are offering. That can lead to further opportunities in terms of M&A options which can come out of those specific alliances on the distribution and marketing side. WSR: In conclusion, what are the most compelling reasons one would invest in Arthro Kinetics? AKI: We can offer a real transformational technology, providing a whole new option of care in-between conservative pain management and joint replacement, both which will still have a place going forward, but in-between that, a regenerative option that can be administered in a minimally-invasive fashion. This would be provide a significant option to the therapies that are out there. We are putting the infrastructure and the people in place that are experienced and have a track record to show we can realize these growth potentials with this combination of technologies. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
